Loading...
•
Dec 31, 2019
Quanterix Q4 2019 Earnings Report
Announced financial results with a revenue growth of 46% for the quarter and 51% for the full year.
Key Takeaways
Quanterix Corporation reported strong Q4 2019 financial results, marking its ninth consecutive quarter of strong performance since going public. The company saw significant growth and technology adoption, particularly with its Simoa technology for measuring novel biomarkers.
Achieved 46% revenue growth in Q4 2019.
Experienced 51% revenue growth for the full year 2019.
Expanded the utility of Simoa technology for measuring biomarkers like neurofilament light chain (Nf-L).
Acquired UmanDiagnostics to secure the supply of Nf-L antibodies.
Forward Guidance
Quanterix enters 2020 with a solid lineup of new differentiated instruments, serum-based biomarker assays, specialty pharma services and compelling validation stemming from over 650 Simoa-specific inclusions in publications. These advances, plus adoption momentum in drug development, are increasing the longer-term promise for our technologies in the larger, potentially more attractive, clinical landscape.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...